Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Rhabdomyosarcoma and Its Risk Factors in Adults

Lin Ye

Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma and represents a high-grade neoplasm of skeletal myoblast-like cells. A gradual improvement in understanding of physiology has helped optimize clinical care. Two main subtypes of RMS. Originally characterized by features of optical microscopy. Driven by fundamentally different molecular mechanisms, it poses a variety of clinical challenges. Curative therapies depend on control of the primary tumor. It can occur in many different anatomical locations. Combat common ailments known or suspected to be present in all cases. Refined risk stratification for children with RMS includes a variety of clinical, pathological and molecular characteristics; this information is used to guide the application of multifaceted treatments. Such treatments have historically included both cytotoxic chemotherapy and ionizing radiation or both. This introduction describes the current understanding of the epidemiology of RMS. Factors of clinical care, including disease susceptibility factors; disease mechanisms; and diagnosis. Risk-based care for newly diagnosed and recurrent disease. Prevention and treatment of late complications in survivors.